KOBO Biotech

KOBO Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KOBO Biotech (531541.BO) as of Oct 29, 2026 is -8.73 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -14.96 M INR — a change of -41.70% (higher).

EBITDA

-8.73 MINR

YoY

-41.70%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KOBO Biotech is 2024 -8.73 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KOBO Biotech was 2023 -14.96 M INR. It decreases by -41.70% higher compared to the previous year.

The KOBO Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-39.40 M INR
Jan 1, 2018
-30.30 M INR
Jan 1, 2019
-29.90 M INR
Jan 1, 2020
-26.10 M INR
Jan 1, 2021
-22.00 M INR
Jan 1, 2022
-105.00 M INR
Jan 1, 2023
-14.96 M INR
Jan 1, 2024
-8.73 M INR
The KOBO Biotech EBITDA history
YEAREBITDAYoY
-8.73 MINR-41.70%
-14.96 MINR-85.75%
-105.00 MINR+377.27%
-22.00 MINR-15.71%
-26.10 MINR-12.71%
-29.90 MINR-1.32%
-30.30 MINR-23.10%
-39.40 MINR-182.08%
48.00 MINR-150.74%
-94.60 MINR+928.26%
-9.20 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

KOBO Biotech Stock analysis

What does KOBO Biotech do? Kobo Biotech Ltd. focuses on manufacturing active pharmaceutical ingredients (APIs)/bulk drugs. The company operates within the pharmaceuticals sector, producing bulk drugs for the industry. Its primary market segment consists of pharmaceutical manufacturers seeking reliable API suppliers. The firm's Solapur site in India is currently inactive, with no operational activities ongoing there. The company's revenue streams derive from the sale of manufactured APIs and bulk drugs to pharmaceutical companies. These products are essential components in the production of finished pharmaceutical formulations. Kobo Biotech Ltd. serves as a key supplier within the pharmaceutical supply chain, providing critical raw materials to its clients. The business model centers on bulk drug manufacturing, with the company acting as a supplier to other pharmaceutical firms. There are no additional product lines or services mentioned beyond API and bulk drug production. The firm's focus remains strictly on the manufacturing of active pharmaceutical ingredients and bulk drugs for the pharmaceutical industry. KOBO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KOBO Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KOBO Biotech is -8.73 M INR in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of KOBO Biotech changed from -14.96 M INR to -8.73 M INR, representing a -41.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) KOBO Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KOBO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — KOBO Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — KOBO Biotech